Drug
Gts-21 clinical trials
Also written GTS-21 and DMXB-A.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2004
How studies write it
Studies that test it under each name
Development codes
Other names
Combined with it in one product
Studies by the year they started
9 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2011 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 8
University of Colorado, Denver (5) · Radboud University Medical Center (1) · CoMentis (1) · University of Florida (1) · VA Office of Research and Development (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses gts-21 is read from its arms, and is right about nine times in ten.
Testing it · 9
- Nicotinic Agonist Effects on BMI and Neuronal ResponseCompletedPhase 1University of Colorado, DenverNCT02458313Written as DMXB-A
- Phase 2 Trial of a Nicotinic Agonist in SchizophreniaCompletedPhase 2University of Colorado, DenverNCT00100165Written as 3-(2,4 dimethoxybenzylidene anabaseine) 150 mg
- Nicotinic Receptors and SchizophreniaCompletedPhase 2University of Colorado, DenverNCT01400477Written as DMXB-A-SR
- Effects of GTS-21 on Smoking Behavior and Neurocognitive FunctionsWithdrawnPhase 2University of FloridaNCT02432066Written as GTS-21
- Nicotinic Receptors and SchizophreniaWithdrawnPhase 1/2VA Office of Research and DevelopmentNCT02538081Written as Risperidone plus DMXB-A
- Phase I Nicotinic Agonist Treatment Trial for AutismTerminatedPhase 1University of Colorado, DenverNCT02111551Written as DMXB-A 150 mg
- Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia PatientsCompletedPhase 1University of Colorado, DenverNCT00255918Written as Dimethoxybenzylidene anabaseine (DMXB-A)
- Anti-inflammatory Effects of GTS-21 After LPSCompletedNot applicableRadboud University Medical CenterNCT00783068Written as GTS-21, [3-(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride]
- GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer's DiseaseCompletedPhase 2CoMentisNCT00414622Written as DMXB-A
Codes
What other systems call gts-21 · ClinicalTrials.gg INT003799
- MeSH (NLM) C0889363-(2,4-dimethoxybenzylidene)anabaseineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 8S399XDN2KGTS-21Confirmed NLM, Wikidata
- Wikidata Q5514756GTS-21Confirmed NLM, Wikidata
- DrugBank DB05708One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C088936 | 3-(2,4-dimethoxybenzylidene)anabaseine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 8S399XDN2K | GTS-21 | Confirmed NLM, Wikidata |
| Wikidata | Q5514756 | GTS-21 | Confirmed NLM, Wikidata |
| DrugBank | DB05708 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.